Afriflu2--second international workshop on influenza vaccination in the African continent--8 November 2012, Cape Town (South Africa)

Abstract

The second meeting of the Afriflu conferences took place in Cape Town, South Africa, with over 60 participants from 15 countries in Africa and also outside the continent. Significant progress in surveillance has been made in better understanding the illness burden of influenza on the continent, which limited evidence suggests is greater than that in the developed world. In southern Africa HIV and TB coinfections play a major role in increasing hospitalisation and mortality, while elsewhere in Africa other cofactors still need to be determined. There is currently no indigenous vaccine production in sub-Saharan Africa and only one facility, based in South Africa, capable of filling imported bulk. Innovative vaccine strategies will need to be explored, such as maternal immunisation, and also the possibility of other influenza vaccine options, such as live attenuated influenza vaccine for young children. Sustained indigenous vaccine production is essential for the continent to have vaccine security in the event of a pandemic even though establishing local production faces considerable challenges especially ensuring adequate markets on the continent. There is an urgent need to develop effective communication messages for decision makers as well as healthcare workers addressing the importance of influenza even in the face of the major competing health burdens of the continent.

Keywords: Africa; Conference report; DCVMN; ILI; Illness burden; Influenza; LAIV; Priority groups; SAGE; SARI; TIV; Vaccine security; Vaccines; WHO; World Health Organization; developing countries vaccine manufacturers network; influenza-like illness; live-attenuated influenza vaccine; severe acute respiratory illness; strategic advisory group of experts on immunisation; trivalent inactivated influenza vaccine.